Glenmark Pharmaceuticals informs about media release
Glenmark Pharmaceuticals has informed that the company has received final approval by the United States Food & Drug Administration (U.S. FDA) for Fluticasone Propionate Nasal Spray USP, 50 mcg per spray (OTC). Glenmark’s Fluticasone Propionate Nasal Spray USP, 50 mcg per spray (OTC) has been determined by the FDA to be bioequivalent1 to the reference listed drug, Flonase®2 Allergy Relief Nasal Spray, 50 mcg per spray, of Haleon US Holding LLC [NDA – 205434]; and will be distributed in the U.S. by Glenmark Therapeutics Inc., USA. The company has attached media release in this regard.
The above information is a part of company’s filings submitted to BSE.
